HS-10241 + apatinib

HS-10241 + apatinib is an oral combination therapy under investigation for advanced solid tumors, especially non-small cell lung cancer (NSCLC). HS-10241 is a selective small molecule inhibitor targeting the c-MET receptor tyrosine kinase, which is implicated in tumor growth and resistance to EGFR inhibitors. Apatinib is a small molecule anti-angiogenic agent that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), reducing tumor angiogenesis. The rationale for combining HS-10241 and apatinib is to block both MET-driven oncogenic signaling and angiogenesis, aiming to overcome resistance mechanisms and improve antitumor efficacy in solid tumors[1][2][3][5].